Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leon Davis

Internal Medicine Montgomery, AL Medical Doctor

NPI 1265493134 CMS profile 239268

1725 W 4Th St, Montgomery, AL 36106

Open in the dashboard

General payments

$12,563

855 records reported · program years 2019–2025

Research payments

$13,983

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leon Davis of Montgomery, AL is reported in the CMS Open Payments database as having received $12,563 across 855 general payments and $13,983 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,955 111
2024 General $1,888 123
2023 General $2,067 139
2022 General $1,603 114
2021 General $1,583 100
2020 General $1,327 99
2019 General $2,140 169
2019 Research $13,983 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leon Davis
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Leon Davis were reported at $1,955. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Leon Davis Internal Medicine median Middle half National median
2019 $2,140 $159 $48–$570 $163
2020 $1,327 $119 $33–$402 $114
2021 $1,583 $135 $37–$521 $132
2022 $1,603 $141 $42–$496 $149
2023 $2,067 $149 $45–$519 $160
2024 $1,888 $154 $47–$537 $164
2025 $1,955 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,735 147 payments
  2. AbbVie, Inc. $1,085 92 payments
  3. AstraZeneca Pharmaceuticals LP $1,043 62 payments
  4. Novo Nordisk Inc $770 53 payments
  5. Dexcom, Inc. $736 66 payments
  6. Merck Sharp & Dohme Corporation $572 46 payments
  7. Abbott Laboratories $515 30 payments
  8. Ardelyx, Inc. $429 21 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $406 21 payments
  10. Kowa Pharmaceuticals America, Inc. $401 24 payments
  11. Other $4,872 293 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,458 851 payments
  2. Education $105 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,416 120 payments
  2. Dexcom G6 Transmitter $710 64 payments
  3. Ozempic $623 43 payments
  4. FARXIGA $534 27 payments
  5. IBSRELA $429 21 payments
  6. RYBELSUS $425 27 payments
  7. Kerendia $406 21 payments
  8. JANUVIA $386 35 payments
  9. UBRELVY $367 25 payments
  10. VRAYLAR $346 35 payments
  11. Other $10,614 701 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $13,983 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 242 drugs

Part D claims

28,901

Median for Internal Medicine: 777

Drug cost

$4,279,683

Median for Internal Medicine: $73,373

Branded share of claims

25.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 271 $383,928
Jardiance Empagliflozin Brand 268 $359,989
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 469 $344,004
Ozempic Semaglutide Brand 203 $274,081
Farxiga Dapagliflozin Propanediol Brand 232 $253,968
Mounjaro Tirzepatide Brand 187 $240,812
Linzess Linaclotide Brand 205 $214,258
Rybelsus Semaglutide Brand 150 $208,774
Eliquis Apixaban Brand 206 $200,481
Vraylar Cariprazine Hcl Brand 90 $143,672

The 10 drugs with the highest cost, of 242 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$110,751

Of which drugs: $4,381

Medicare patients

230

Average age 72

Services billed

3,193

108 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 48%
Chronic kidney disease 36%
Ischemic heart disease 25%
Heart failure 20%
Cancer 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 20 20 $438
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 28 51 $38
Injection, ceftriaxone sodium, per 250 mg J0696 Office 20 69 $23
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 51 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$183 469 —
IBSRELA
$152 12 —
FARXIGA
$129 232 —
UBRELVY
$124 11 —
AIRSUPRA
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

859 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record